Molecular diagnostics company Cepheid helped to bring together prominent scientists and clinicians from across the UK at the recent British Association for Sexual Health and HIV (BASHH) Spring Meeting, where the latest healthcare trends and scientific breakthroughs in this important field were discussed.
Cepheid showcased the latest addition to the GeneXpert test menu, Xpert CT/NG, and sponsored a lecture on assessing the costs and benefits of point-of-care tests for sexually transmitted infections.
The Xpert CT/NG qualitative in vitro molecular diagnostic test detects and differentiates Chlamydia trachomatis and Neisseria gonorrhoeae. It is an easy-to-use, FDA-approved and CE-marked, on-demand molecular test which uses two independent Neisseria DNA targets for high specificity and a Chlamydia target selected for superior inclusivity. Results are delivered in just 90 minutes, contributing to effective patient and disease management.
www.cepheidinternational.com
